Edition:
United Kingdom

People: Amarin Corporation PLC (AMRN.OQ)

AMRN.OQ on NASDAQ Stock Exchange Global Market

21.74USD
16 Jul 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$21.74
Open
$21.87
Day's High
$21.93
Day's Low
$21.53
Volume
761,976
Avg. Vol
1,603,695
52-wk High
$23.91
52-wk Low
$2.36

Ekman, Lars 

Dr. Lars G. Ekman, M.D., Ph.D., has been appointed as Independent Chairman of the Board of Amarin Corp Plc., effective January 1, 2014. With more than 29 years of experience in the pharmaceutical industry, Dr. Ekman is currently an executive partner at Sofinnova Ventures and serves as Executive Chairman of Sophiris Bio Inc. (formerly Protox Therapeutics) as well as Chairman of Prothena Biosciences. From October 2008 to 2011 he served as Co-Founder and Chief Executive Officer of Cebix Inc. He was Executive Vice President and President of Global Research and Development at Elan Corporation plc, from January 2001 to December 2007. Prior to joining Elan, he was Executive Vice President, Research and Development at Schwarz Pharma AG from February 1997 to December 2000, and prior to that was employed in a variety of senior scientific and clinical functions at Pharmacia, now Pfizer. Dr. Ekman also sits on the board of directors of InterMune Inc. and Ocera Therapeutics. Dr. Ekman is a board-certified surgeon with a Ph.D. in experimental biology and has held several clinical and academic positions in both the United States and Europe. He obtained his Ph.D. and M.D. from the University of Gothenburg, Sweden. Based on Dr. Ekman’s experience within the pharmaceutical industry and his executive experience, specifically his experience as Chief Executive Officer and other executive positions in the biotechnology industry, as well as his service on boards of directors in the biotechnology industry, the Board believes Dr. Ekman has the appropriate set of skills to serve as a member of our Board.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Lars Ekman

--

John Thero

2,769,490

Michael Kalb

--

Stephen Ketchum

1,198,590

Joseph Kennedy

1,201,640

Aaron Berg

--
As Of  31 Dec 2014